Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin

Author： Kadokura Takeshi   Groenendaal Dorien   Heeringa Marten   Mol Roelof   Verheggen Frank   Garcia-Hernandez Alberto   Onkels Hartmut  

Publisher： Springer Publishing Company

ISSN： 0378-7966

Source： European Journal of Drug Metabolism and Pharmacokinetics, Vol.39, Iss.1, 2014-03, pp. : 1-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban

By Apostolakis Stavros   Lip Gregory YH  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 1057-1064

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Absence of Clinically Relevant Interactions between Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects

By Kubitza D   Becka M   Roth A   Mueck W  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1688-1707

Field House Publishing

Access to resources Recommend Favorite

Edoxaban: A New Oral Direct Factor Xa Inhibitor

By Camm A. John  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1503-1526

Adis International

Access to resources Recommend Favorite